EGR1 and chronic myelogenous leukemia, BCR-ABL1 positive: Our data indicate that a novel pathway is present in TKI-resistant CML, and EGFRΔIII GBM, cells whereby NOX2 is elevated and activated leading to increased levels of ROS and subsequent Egr-1 protein expression resulting in proliferation and survival of resistant cells (Figure 7B).